Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
07:00am, Wednesday, 12'th Nov 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. As
NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript
03:16pm, Thursday, 30'th Oct 2025
NovoCure Limited ( NVCR ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Ingrid Goldberg - VP of Investor Relations William Doyle - Executive Chairman Ashley Cordova - CEO & D
Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics
11:30am, Thursday, 30'th Oct 2025
The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street est
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
09:20am, Thursday, 30'th Oct 2025
NovoCure (NVCR) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.28 per share a year ago.
Novocure Reports Third Quarter 2025 Financial Results
07:00am, Thursday, 30'th Oct 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to exten
NovoCure (NVCR) Projected to Post Quarterly Earnings on Thursday
02:39am, Thursday, 23'rd Oct 2025
NovoCure (NASDAQ: NVCR - Get Free Report) will likely be announcing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of ($0.42) p
NovoCure Limited $NVCR Shares Purchased by KLP Kapitalforvaltning AS
04:16am, Sunday, 19'th Oct 2025
KLP Kapitalforvaltning AS raised its stake in NovoCure Limited (NASDAQ: NVCR) by 6.5% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Comm
NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum
07:55am, Friday, 17'th Oct 2025
Novocure Limited (NVCR) is rated BUY, driven by expanding regulatory approvals, breakthrough clinical results, and a robust late-stage pipeline in cancer therapy. NVCR's Tumor Treating Fields technolo
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meetin
Novocure to Report Third Quarter 2025 Financial Results
07:00am, Wednesday, 01'st Oct 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management wi
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small ce
NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
05:53pm, Wednesday, 10'th Sep 2025
NovoCure Limited (NASDAQ:NVCR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 3:20 PM EDT Company Participants Ashley Cordova - CEO & Director Conference Call Participants
Novocure Announces Upcoming Investor Events
07:00am, Thursday, 28'th Aug 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in three upcoming investor events. 2025 Wells Fargo Healthcare Conference, September 4, 202
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
07:00am, Monday, 25'th Aug 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Spain's Ministry of Health has made Tumor Treating Fields (TTFields) therapy available through the Spanish National Hea
NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer
02:40pm, Friday, 22'nd Aug 2025
NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.
